Do you want to specify the immunoreactivity of your sample ?
BIA technology allows the detection of antidrug antibodies.

Newly designed pharmaceuticals can cause an unwanted immune response. In preclinical studies such potentials can be recognised during animal studies. BIA technology allows the detection of antibodies against new drugs in animal serum samples.

Biaffin offers assay development and the performance of assays to detect antibodies in serum samples with a new drug immobilised on a chip surface (as the “antigene”). With appropriate control experiments positive binding signals of low levels of antibodies can clearly be identified as a specific signal despite of the complexity of the protein mixture in serum samples.


Furthermore, a subtype classification of bound antibodies identifying them as IgG or IgM antibodies is possible using suitable secondary antibodies in a subsequent sandwich experiment.


Please ask for an individual quote that meets your requirements.

Our service: 

  • characterization of the humoral immune response in serum samples upon drug candidate exposure
  • detection of antidrug antibodies (ADAs) 
  • quantification of ADAs, isotyping, specificity and determination of binding stability 
BIAFFIN GmbH & Co KG | Heinrich-Plett-Str. 40 | D-34132 Kassel | Germany
Tel.: +49 (0) 561-804 4661 | Fax: +49 (0) 561-804 4665 |

We value your privacy

In order to optimize our website for you and to be able to continuously improve it, we use cookies. Further information is available in our Data Protection Statement. Here you can find our Legal Information.